TIDMOPTI
RNS Number : 2205Z
OptiBiotix Health PLC
17 September 2020
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Exclusive distributor agreement with Ayalla Marketing
Deal signed by Probiotix Health Ltd
OptiBiotix Health p lc (AI M: OPTI), a life sciences busi ness d
eveloping compou n ds to tackle obesity, high cholesterol, diabetes
and skin care, announces that its wholly-owned subsidiary,
ProBiotix Health Ltd ("ProBiotix"), has entered into an exclusive
distribution agreement with Ayalla Marketing ("Ayalla") for the
distribution of its cholesterol reducing probiotic, LP(LDL) (R), as
an ingredient and as four finished products (CholBiome,
CholBiome(X3) , CholBiome(BP) and CholBiome(VH) ) within the
CholBiome(R) portfolio for Brazil.
The new agreement:
-- Includes distribution of LP(LDL) (R) as bulk ingredient; as
well as four additional products: CholBiome, CholBiome(X3) ,
CholBiome(BP) and CholBiome(VH)
-- Offers an agreed and expected first order within 30 days from
approval of the authorities of both the ingredient LP(LDL) (R), as
well as one of the CholBiome products
The agreement is for an initial period of 12 months and has
modest minimum order quantities for each product providing the
Company security of income and revenue growth.
Ayalla was founded in 1973 with the purpose of providing APIs
(Active Pharmaceutical Ingredients) for the pharmaceutical
industry. The company has a diverse product portfolio developed to
meet the need of veterinary, food, cosmetics and fragrance
industries. It has three business units: Pharmaceuticals,
Nutraceuticals, and Technologies which includes bringing new drug
molecules to market. LP(LDL) (R) will be distributed by its
Nutraceutical business unit. Ayalla has developed a network of
suppliers in Europe, the U.S. and Asia, which enables the company
to offer high quality products and services and is a well-known and
established distributor of pharmaceutical and nutraceutical
products in Brazil.
Cardiovascular diseases (CVD), are estimated to account for 28%
of all deaths in Brazil in the last five years and for 38% of
deaths in the productive age range (18 to 65 years). The estimated
costs of CVD were $6.9billion USD in 2015, a 17% increase in the
period from 2010 to 2015(1) . Whilst statins remain the first
choice of drug treatment, non-drug treatment including exercise and
the use of nutritional supplements are increasingly being seen by
clinicians and health care professionals as a naturally safe and
effective approach to reducing cardiovascular risk.
1. Analysis of the Economic Impact of Cardiovascular Diseases in
the Last Five Years in Brazil Arq. Bras. Cardiol. vol.109 no.1 São
Paulo July 2017 Epub June 01, 2017
Mikkel Hvid-Hansen, Commercial Director of ProBiotix Health
commented: "We are pleased to announce the signing of this
distribution agreement with Ayalla. Ayalla is an established
distributor with a national reputation and wide network of
contacts. We chose Ayalla because of its reputation and expertise
in commercialising pharmaceutical and non-drug products with strong
science and clinical studies in the Brazilian market."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
Enquires:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
finnCap (Broker) Tel: 020 7220 0500
Geoff Nash / Kate Bannatyne (Corporate Finance)
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D programme working with
leading academics in the development of microbial strains,
compounds, and formulations which are used as active ingredients
and supplements. More than twenty international food and healthcare
supplement companies have signed agreements with OptiBiotix to
incorporate their human microbiome modulators into a wide range of
food products and drinks.
OptiBiotix is also developing its own range of consumer
supplements, and health snacks and food products. The Company's
current areas of focus include obesity, digestive health,
cardiovascular health, and diabetes.
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed
to be, forward looking statements. Forward looking statements are
identi ed by their use of terms and phrases such as "believe",
"could", "should" "envisage", "estimate", "intend", "may", "plan",
"potentially", "expect", "will" or the negative of those,
variations or comparable expressions, including references to
assumptions. These forward looking statements are not based on
historical facts but rather on the Directors' current expectations
and assumptions regarding OptiBiotix's future growth, results of
operations, performance, future capital and other expenditures
(including the amount, nature and sources of funding thereof),
competitive advantages, business prospects and opportunities. Such
forward looking statements re ect the Directors' current beliefs
and assumptions and are based on information currently available to
the Directors.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGRLFMATMTTBBRM
(END) Dow Jones Newswires
September 17, 2020 02:00 ET (06:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Sep 2024 to Oct 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Oct 2023 to Oct 2024